Jump to content
  • charter.pngrrdiLogo384x64.jpg.3cd1bd79f5d066075bdd9

    The purpose of the Rosacea Research & Development Institute [RRDi] is to fund research and development for finding a cure for rosacea by establishing a Medical Advisory Committee [MAC] of the best available minds on rosacea and to publish the results of this endeavor to the public and professional groups. This MAC will provide the direction of the research. Research may also include studying various treatments for the control of rosacea in multi-center, double blind, placebo controlled clinical trial studies. The RRDi is commited to support patient advocacy for those suffering from rosacea. This organization is open to the public and membership is free and has been organized by rosaceans for rosaceans. This organization is a non-profit corporation registered in the State of Hawaii and 501 (c) (3) tax-exempt status approval has been obtained from the IRS effective June 7, 2004. The Articles of Incorporation, the Bylaws, and the Conflict of Interest Policy are available for the public.

     

    Membership is open to the public and is free. Rosaceans are specially invited to join. All who join providing contact information become members of the corporation and for now this number is not limited but may be revised in the future by the institute. There are two categories of members: 

    Voting Member (a member who choses voluntarily to provide contact information, i.e., first and last name, mailing address and phone number, email addresses)

    Non Voting Member (a member who only provides one email address)

    An Active Member is one who has posted within the last thirty days and has full access to the RRDi website. An Inactive Member is one who has not posted in the last thirty days and is therefore restricted to guest privlieges of access to the site until such time as the member becomes active again and full access to the site is restored. Any SUBSCRIBED member is not restricted to post within thirty days. Volunteer Active Members may waive the subscription fee. 

    A rosacean is anyone who is diagnosed by a physician as having rosacea. All that is necessary to be designated a voting member is a statement from the member that a diagnosis of rosacea has been obtained from a physician as well as the contact information mentioned above for voting members. Voting members should be rosacea sufferers (rosaceans). 

    Non-rosaceans are permitted to join and should identify themselves as such upon demand from the institute. Non-rosaceans are those who have not obtained a diagnosis of rosacea by a physician. 

    Any member of the institute may be removed from the membership at any time at the sole discretion of the institute. Rules of the institute are published and available to the public. Violation of the rules may be grounds for termination as a member of the institute. Membership in the institute is a privilege.

    Funding will provide a rosacea MAC of the best available minds on finding a cure for this disease. The selection of who is chosen to be in this MAC will be based on not only the qualifications of the individual but also from nominations by both rosacean and non rosaceans members of the institute.

    Sources of funding to the institute will be publicized including the name of the donor unless the donor requests anonymity. Expenses of the institute will be publicized down to the last cent, showing where all the spending went and for what purpose since transparency is a core principle of our non profit organization. 

    The philosophy and spirit of this institute is that funding should predominately be used for research and development and not for the administration of the institute. Volunteers are an integral part of this spirit and we hope to include member rosaceans and non-rosaceans who are willing to help the purpose of the institute become a reality. We need your help to find a cure for rosacea, to research rosacea, to publish the findings of this research and provide a MAC of the best available minds on rosacea. The views and suggestions of rosaceans will be an integral part in directing the research on rosacea, in choosing the MAC and the directors of the institute. Voting members of the institute will have a voice in the decision making of the institute, although directors of the institute will make all final decisions.

    Members of the institute will not profit from the institute however the Medical Advisory Committee members or members may be compensated for services rendered to the institute.

    Voting members will elect a board of directors that includes:

    Director, Assistant Director, Secretary, Treasurer and/or other board members. The board of directors will decide all matters of the institute and will be volunteers.

    Funding on rosacea research by the RRDi will not be used on animal testing.

    Our Mission Statement may be read by clicking here.

    This charter may be revised from time to time by the institute when deemed appropriate at the sole discretion of the institute.



  • Posts

    • Expert Rev Clin Immunol. 2022 Sep 22. doi: 10.1080/1744666X.2022.2128334. Online ahead of print. ABSTRACT INTRODUCTION: : Recent advances in the understanding of the pathophysiology of rosacea have led to increased focus on the disease's immunologic etiology and to the development of immunologically based treatments. With many patients suffering from incomplete control, addressing the immune components of the disease process may provide a more effective treatment option for rosacea patients that may improve quality of life. AREAS COVERED: : This review will provide a brief overview of the pathophysiology or rosacea, as well as specific immunologic contributions to the disease state. Current standard-of-care treatments will be described, including anti-parasitic, anti-inflammatory agents, and antibiotics. Emphasis will be placed on treatments that target the immune components of the disease process. EXPERT OPINION: : Rosacea remains a difficult dermatologic disease to treat, partially due to an incomplete understanding of the disease pathophysiology. The immune pathophysiology of rosacea, particularly the key role of inflammation, has been clarified over the past decade. Identification of specific molecules, including cytokines and nuclear transcription factors, may allow for the development of targeted rosacea-specific biologic and topical treatments. However, medication nonadherence is a limiting factor to achieving symptomatic control among rosacea patients. Focusing on the development of oral or injectable forms of therapy may circumvent poor adherence. PMID:36137266 | DOI:10.1080/1744666X.2022.2128334 {url} = URL to article
    • J Cosmet Dermatol. 2022 Sep 20. doi: 10.1111/jocd.15271. Online ahead of print. NO ABSTRACT PMID:36126208 | DOI:10.1111/jocd.15271 {url} = URL to article
    • JAAD Case Rep. 2022 Jul 19;28:83-86. doi: 10.1016/j.jdcr.2022.07.014. eCollection 2022 Oct. NO ABSTRACT PMID:36105757 | PMC:PMC9467856 | DOI:10.1016/j.jdcr.2022.07.014 {url} = URL to article
    • Cureus. 2022 Sep 3;14(9):e28726. doi: 10.7759/cureus.28726. eCollection 2022 Sep. ABSTRACT Facial hypervascularity is a condition that manifests as erythema and edema caused by aberrant blood vessels. Often, the cause of these abnormal blood vessels can be attributed to previous trauma or vascular conditions such as rosacea, although sometimes the cause is unknown. Pulsed dye laser (PDL) can be an effective treatment even when the cause is unknown. We present a case of a 24-year-old male presenting with intermittent swelling, redness, and throbbing sensations of the nose and cheeks for the past five years. Physical examination was notable for prominent erythema and swelling of the nasal skin and mild erythema on the cheeks. He underwent treatment with PDL and achieved complete resolution of his symptoms. This case illustrates the effectiveness of PDL in the treatment of facial hypervascularity. PMID:36105901 | PMC:PMC9447474 | DOI:10.7759/cureus.28726 {url} = URL to article
    • J Dtsch Dermatol Ges. 2022 Sep 13. doi: 10.1111/ddg.14879. Online ahead of print. ABSTRACT This guideline aims to improve the efficiency and safety of lasers and optical radiation sources with similar effects (especially IPL). Laser therapy of skin lesions with an increased amount of melanocytes should be performed with caution. Laser treatment of pigmented melanocytic nevi is not recommended. The guideline contains recommendations regarding the treatment of lentigines and café-au-lait spots, non-pigmented dermal nevi, Becker nevus, nevus of Ota/Hori/Ito and melasma. Further recommendations focus on the treatment of skin lesions without an increased amount of melanocytes (ephelides, postinflammatory hyperpigmentation including berloque dermatitis, seborrheic keratoses, traumatic/decorative tattoos and metallic deposits), hypopigmentation (vitiligo), benign non-pigmented neoplasms (fibrous papule of the nose, nevus sebaceus, epidermal nevus, neurofibroma, sebaceous gland hyperplasia, syringoma, xanthelasma palpebrarum), inflammatory dermatoses (acne papulopustulosa/conglobata, acne inversa, granuloma faciale, lichen sclerosus, lupus erythematosus, psoriasis vulgaris, rosacea, rhinophyma), wrinkles/dermatochalasis/striae, hypertrichosis, scars (atrophic, hypertrophic; keloids, burn/scald scars), laser-assisted skin healing, onychomycosis, precancerous lesions and malignant tumors (actinic keratoses/field cancerization, cheilitis actinica, basal cell carcinoma), vascular skin lesions (angiokeratoma, angioma, hemangioma, malformation, spider veins, granuloma telangiectaticum (pyogenic granuloma), rubeosis (erythrosis interfollicularis colli, ulerythema ophryogenes), nevus flammeus, telangiectasias and Osler's disease (hereditary hemorrhagic telangiectasia) and viral skin lesions (condylomata acuminata, mollusca contagiosa, verrucae planae juveniles/vulgares/ verrucae palmares et plantares). PMID:36098675 | DOI:10.1111/ddg.14879 {url} = URL to article
×
×
  • Create New...

Important Information

Terms of Use